By the Top Tier Newswire AI Desk · July 27, 2026 at 11:22 AM ET · reviewed against 10 wire stories
CAPRICOR THERAPEUTIC (CAPR) is drawing unusual attention today. Our newswire has captured 10 stories on CAPR across 10 sources in the last 36 hours, with AI sentiment reading bearish (avg 39/100).
Why CAPR stock is moving today
Capricor Therapeutics stock is moving sharply lower today, with shares plunging over 67% from their opening price of $18.60 to a low of $5.25 in early trading. The move follows the release of FDA briefing documents ahead of a July 29 advisory committee meeting on deramiocel, the company's lead therapy for Duchenne muscular dystrophy-related cardiomyopathy. The FDA raised concerns about the therapy's efficacy and safety, casting doubt on its potential for regulatory approval.
What Happened
The FDA released briefing documents that questioned whether deramiocel has demonstrated sufficient effectiveness in treating cardiomyopathy in patients with Duchenne muscular dystrophy. The agency stated that its reviewers were unable to identify a subpopulation that may potentially derive benefit from the treatment after extensive analysis of the data. Capricor responded by defending its clinical results and arguing that the FDA's analysis relies on an obsolete plan. The company emphasized the strength of its late-stage therapy data ahead of the influential advisory committee meeting.
The stock opened with a -5.6% gap from the prior close and continued to fall throughout the session, reaching a 52-week low. The sharp decline reflects investor concerns over the FDA's skepticism and the potential impact on the company's regulatory pathway. Additionally, recent insider transactions show multiple executives selling shares, adding to the bearish sentiment.
What The Data Shows
Capricor's stock has traded between $4.30 and $40.37 over the past 52 weeks. The current session has seen a volume of 12.2 million shares, which is 9.5 times the 3-month daily average. The stock opened at $18.60 and reached a high of $19.04 before plummeting to $5.25. The last traded price is $6.31. Over the last 8 sessions, the stock has moved -3.2%, from $20.35 to $19.70. Recent insider filings show 0 buys and 4 sells totaling $1.5 million in the last 90 days, with the most recent sale on June 29.
What To Watch
The July 29 FDA advisory committee meeting will be a key event to monitor for further clarity on deramiocel's regulatory prospects. Investors should also track coverage breadth and analyst ratings in the coming days.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.